WEST PALM BEACH, Fla., Jun 19, 2014 (BUSINESS WIRE) — Tyrogenex Inc. , an Xcovery Group company focused on discovering and developing novel patented cancer and ophthalmic therapeutics, today announced it received $15 million in Series D financing from Brace Pharma, the U.S. investment company of EMS S/A, the largest pharmaceutical company in Brazil. Vinzenz Ploerer, president and CEO of Brace Pharma, was appointed to the Board of Directors for Tyrogenex, Inc.
Brace Pharma Capital
Bringing Innovative Medicines to Patients